An observational study in Non Small Cell Lung Cancer, sponsored by Armando Santoro, MD. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-10.
Sponsored by Armando Santoro, MD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy — 156 open to participants now, 286 under way, 104 of them phase 3. Carcinoma, Non-Small-Cell Lung · Italy.
Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, this one is the 17th largest by enrollment of the 67 observational ones that give a count, is one of 15 that started in 2007, is one of 67 observational ones, and was the 96th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →156 of the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Italy, United States, Argentina and 10 more countries
Ages 18+
Hoffmann-La Roche · Sites in Italy, United States, Argentina and 16 more countries
Ages 18+
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18+ · Healthy volunteers
Bristol-Myers Squibb · Sites in Italy, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
716 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 291 · Phase 3 265 · Phase 4 6
First in 1994; this study’s year is marked. 15 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 454 is above the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 251 across the 640 interventional studies, 200 across the 67 observational. Of the 387 that completed or were terminated, 243 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
560 of 716 have an industry lead sponsor. The 10 most frequent:
Armando Santoro, MD is the lead sponsor of 18 studies on the registry; 1 is open to participants now.
Armando Santoro, MD has 4 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
67 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Italy that are under way reach primary completion within a year, 19 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT06430866Phase 3AmgenPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) | 2026-12-14 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05609968Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | 2027-01-12 |
Add all 67 to your calendar (.ics) → With an account.
Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients
The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.
Radically resected non small cell lung cancer patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Radically resected Non small cell lung cancer patients in stage I-III
Genetic: Protein expression by immunohistochemistry and immunofluorescence
Protein expression by immunohistochemistry and immunofluorescence
Association of different biomarkers with survival
Time frame: At the end of enrollment
Association of a specific biomarker with patient's characteristics
Time frame: At the end of enrollment
The record gives a start of Nov 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Armando Santoro, MD